IP Library Granted Patent US 10,751,072
Granted Patent B2
US 10,751,072 · App. 15/401,950 · Granted Aug 25, 2020

Delivery device

Inventor: Mark Anthony Fernance Kendall (Queensland, AU)
Assignee: VAXXAS PTY LIMITED
A61B17/205A61M37/0015A61M2037/0046B33Y80/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,751,072
App. No.
15/401,950
Granted
Aug 25, 2020
Kind
B2
Abstract

A device for delivery of material or stimulus to targets within a body to produce a desired response, the targets being at least one of cells of interest, cell organelles of interest and cell nuclei of interest. The device includes a number of projections for penetrating a body surface, with the number of projections being selected to produce a desired response, and the number being at least 500. A spacing between projections is also at least partially determined based on an arrangement of the targets within the body.

Claims (26)

1. A device for delivery of antigen(s) to targets within a body to produce an immunological response, the device comprising:

a) a solid base;

b) two or more projections extending from the base, the projections comprising a targeting section for delivering the antigen(s) to the targets to thereby cause the immunological response and a cylindrical support section for supporting the targeting section, wherein two or more steps exist between the targeting section and the support section and the support section is wider than the targeting section such that the steps interact with the body surface, wherein the steps face the body surface;

c) the number of projections is selected to deliver the antigen(s) to a number of targets that is at least sufficient to produce the immunological response, the number of projections being at least 500; and

d) at least part of at least some of the projections are coated with non-liquid antigen(s).

2. The device of claim 1 wherein the antigen(s) are from pathogenic organisms.

3. The device of claim 2 wherein the pathogenic organisms are selected from pathogenic organism that cause diseases from the group consisting of measles, diphtheria, pertussis, tuberculosis, tetanus, cholera, botulism, mumps, rubella, poliomyelitis, hepatitis A, hepatitis B, hepatitis C, influenza, adenovirus, rabies, dengue and yellow fever and combinations thereof.

4. The device of claim 2 wherein the pathogenic organisms are viruses.

5. The device of claim 4 wherein the viruses are selected from the group consisting of influenza virus, poliovirus, hepatitis viruses, papillomavirus, Ebola virus, Japanese encephalitis virus, human immunodeficiency virus and combinations thereof.

6. The device of claim 2 wherein the pathogenic organisms are bacteria.

7. The device of claim 6 wherein the bacteria are selected from the group consisting of Corynebacterium diphtheria, Bordetella pertussis, Clostridium tetani, Mycobacterium tuberculosis, Haemophilus influenza, Vibri cholera, Bacillus anthracia, Shigella, dysenteriae, Clostridium botulinum, Escherichia coli, Clostridium perfringens, Pseudomonas aeruginosa, Staphylococcus aureus and Streptococcus pyrogens and combinations thereof.

8. The device of claim 1 wherein the antigen(s) are selected from the group consisting of pertussis toxin, filamentous hemagglutinin, pertactin, F M2, FIM3, adenylate cyclase, diphtheria toxin or toxoid, tetanus toxin or toxoid, M proteins mycolic acid, heat shock protein 65 (HSP65), the kDa major secreted protein, antigen 85A, pneumolysin, pneumococcal capsular polysaccharides, capsular polysaccharides, anthrax protective antigen and rompA and combinations thereof.

9. The delivery device of claim 1 wherein the projections are sold, non-porous and non-hollow.

10. The device of claim 1 wherein the number of projections is at least 1000.

11. The device of claim 1 wherein one or more of the projections has a length of between 200 μm to 1000 μm.

12. The device of claim 1 wherein the targeting section of the projection has a tip which is less than 5 μm across.

13. The device of claim 1 wherein the density of the projections is between 100 projections/mm 2 to 500 projections/mm 2 .

14. The device according to claim 1 , wherein at least part of the one or more of the projections are coated with two or more different non-liquid coating materials on the same projection.

15. The device according to claim 1 , wherein at least part of the one or more of the projections are coated with two or more different non-liquid coating materials on different projections.

16. The device of claim 1 wherein the steps comprise one or more parallel sections separated by one or more tapered sections.

17. The device of claim 1 wherein the device is constructed of polymeric material.

18. The device of claim 1 wherein the two or more steps is two steps.

19. The device of claim 1 wherein the density of the projections is at least 100 projections/mm 2 .

20. The device of claim 1 wherein the number of projections is at least 2000.

21. The device of claim 1 wherein the support section has a length of at least 10 μm.

22. The device of claim 1 wherein the device is circular.

Assignments (3)
CHANGE OF ADDRESS Recorded Feb 20, 2018
From: VAXXAS PTY LIMITED
To: VAXXAS PTY LIMITED
Reel/Frame 045640/0798 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 23, 2017
From: THE UNIVERSITY OF QUEENSLAND
To: UNIQUEST PTY LIMITED
Reel/Frame 043368/0707 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 23, 2017
From: UNIQUEST PTY LIMITED
To: VAXXAS PTY LIMITED
Reel/Frame 043456/0271 →
Priority Claims (1)
GB 0402131.7 · Jan 30, 2004 · national
Continuity (4)
Continuation 13251891 · Oct 3, 2011
Continuation 11496053 · Jul 27, 2006
Continuation In Part PCTGB2005000336 · Jan 31, 2005
Related Publication 20170182301A1 · Jun 29, 2017
Cited By (4)
US 12,194,157 US 12,311,061 US 12,409,149 US 12,491,351